(Q50586320)

16 March 2018

title

Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation. (English)

1 reference

16 March 2018

1 reference

liver transplantation

1 reference

P Wietzke

1

1 reference

16 March 2018

F Braun

series ordinal

2

1 reference

16 March 2018

B Ringe

series ordinal

3

1 reference

16 March 2018

G Ramadori

series ordinal

4

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 November 2000

1 reference

16 March 2018

Transplantation Proceedings

published in

1 reference

16 March 2018

volume

32

1 reference

16 March 2018

issue

7

1 reference

16 March 2018

page(s)

2539-2542

1 reference

16 March 2018

Long-term outcome of hepatitis C infection after liver transplantation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Long-term outcome of hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Retransplantation for recurrent hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Cholestatic hepatitis C in liver allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Hepatitis viruses and liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2800%2901782-6

7 January 2021

10.1016/S0041-1345(00)01782-6

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018